PLECONARIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H18F3N3O3
Molecular Weight	381.349
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1

InChI

InChIKey=KQOXLKOJHVFTRN-UHFFFAOYSA-N

InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3

HIDE SMILES / InChI

Description
Sources: https://www.fda.gov/ohrms/dockets/ac/02/briefing/3847b1_01_viropharma.pdf
Curator's Comment: The description was created based on several sources, including https://www.drugbank.ca/drugs/DB05105 | https://www.ncbi.nlm.nih.gov/pubmed/26169596

Pleconaril (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril binds to a hydrophobic pocket in viral protein 1, the major protein which comprises the capsid (the outer "shell") of picornaviruses. In enteroviruses, this prevents the virus from exposing its RNA, and in rhinoviruses, it also prevents the virus from attaching itself to the host cell. The results of two randomized, double-blind, placebo studies found Pleconaril treatment could benefit patients suffering from colds due to picornaviruses. Participants in the studies were healthy adults from Canada and the United States, with self-diagnosed colds that had occurred within 24 hours of trial enrollment. Participants were randomly given a placebo or two 200 mg tablets to take three times daily for five days. To increase absorption it was recommended to be taken after a meal. To monitor the effectiveness of Pleconaril, Participants recorded the severity of their symptoms and nasal mucosal samples were obtained at enrollment, day 3, day 6 and day 18. The two studies had a total of 2096 participates and more than 90% (1945) completed the trial. The most common reason for a participant not finishing the trial was an adverse event. Pleconaril treatment showed a reduction in nose blowing, sleep disturbance, and less cold medication used. The U.S. Food and Drug Administration rejected pleconaril in 2002 due to the side effects. The most commonly reported side effects were mild to a moderate headache, diarrhea, and nausea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Genome polyprotein 5 Target ID: P03303\|\|\|Q84741\|\|\|Q89649 Gene ID: 1461213.0 Gene Symbol: NA Target Organism: Human rhinovirus 14 (HRV-14) Sources: https://www.fda.gov/ohrms/dockets/ac/02/briefing/3847b1_01_viropharma.pdf	Blocker 555
Human rhinovirus A protease 2 Target ID: CHEMBL2857 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11931615	Inhibitor 8504		58.0 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Common cold 58 Sources: https://clinicaltrials.gov/ct2/show/NCT00394914	Primary	Phase II 1147	Unknown Approved Use Unknown
Asthma 244 Sources: https://clinicaltrials.gov/ct2/show/NCT00394914	Primary	Phase II 1147	Unknown Approved Use Unknown
Picornavirus infection 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00394914	Curative	Phase II 1147	Unknown Approved Use Unknown
Enteroviral sepsis 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00031512	Curative	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.44 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.66 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.03 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.39 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.25 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.14 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.46 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1272.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10049279/	5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FED
836 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407253/	8.5 mg/kg 3 times / day steady-state, oral dose: 8.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
3.2 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.67 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
8.76 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
16.21 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
19.11 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
31.14 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
49.3 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
9.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8131.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10049279/	5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FED
6824 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407253/	8.5 mg/kg 3 times / day steady-state, oral dose: 8.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
19.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
35.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
22.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
28.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
27 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10354965/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.74 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9756781/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10049279/	5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FED
22.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407253/	8.5 mg/kg 3 times / day steady-state, oral dose: 8.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	PLECONARIL plasma	Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% REVIEW https://pubmed.ncbi.nlm.nih.gov/12627933/			PLECONARIL unknown	Homo sapiens

Doses

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/10354965/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/10354965/	Other AEs: Syncope... Other AEs: Syncope (grade 1, 12.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/10354965/
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	Other AEs: Headache, Diarrhea... Other AEs: Headache (grade 1-2, 22%) Diarrhea (grade 1-2, 9%) Nausea (grade 1-2, 6%) Bronchitis (grade 1-2, 3%) Rhinitis (grade 1-2, 2%) Sinusitis (grade 1-2, 3%) Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/

AEs

AE	Significance	Dose	Population
Syncope	grade 1, 12.5%	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/10354965/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/10354965/
Rhinitis	grade 1-2, 2%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/
Headache	grade 1-2, 22%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/
Bronchitis	grade 1-2, 3%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/
Sinusitis	grade 1-2, 3%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/
Nausea	grade 1-2, 6%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/
Diarrhea	grade 1-2, 9%	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/12802751/

PubMed

Title	Date	PubMed
The need for treatment against human parechoviruses: how, why and when?	2010-12	21133666
Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.	2010-12	21084040
Clinical features, diagnosis, and management of enterovirus 71.	2010-11	20965438
An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections.	2010-10-11	20937137
Viral meningoencephalitis: a review of diagnostic methods and guidelines for management.	2010-08	20236175
Enterovirus genotype EV-104 in humans, Italy, 2008-2009.	2010-06	20507762
Rhinovirus genome evolution during experimental human infection.	2010-05-11	20485673
Enterovirus 71 infection: An experience in Korea, 2009.	2010-05	21189926
Anti-human rhinovirus activity of raoulic acid from Raoulia australis.	2010-04	20412019
MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference.	2010-03-19	20333250
Human rhinovirus C: a newly discovered human rhinovirus species.	2010	22460392
Antiviral treatments reduce severity of diabetes in Ljungan virus-infected CD-1 mice and delay onset in diabetes-prone BB rats.	2009-10	19780970
Role of rhinovirus C in apparently life-threatening events in infants, Spain.	2009-09	19788827
Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya.	2009-08-23	19698184
New perspectives of infections in cardiovascular disease.	2009-05	20436849
New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.	2009-01	18840470
Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease.	2009	19436697
Novel human rhinoviruses and exacerbation of asthma in children.	2008-11	18976575
Selective inhibitors of picornavirus replication.	2008-11	18381747
Iota-Carrageenan is a potent inhibitor of rhinovirus infection.	2008-09-26	18817582
Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C).	2008-04-02	18382652
Potential use of antiviral agents in polio eradication.	2008-04	18394270
Treatment of viral myocarditis caused by coxsackievirus B.	2008-01-15	18192257
Enterovirus-associated hemophagocytic syndrome in children with malignancy: report of three cases and review of the literature.	2008-01	17318619
A case report of a premature infant with coxsackie B1 meningitis.	2007-10	18049150
WITHDRAWN: Antivirals for the common cold.	2007-07-18	17636705
Fatal coxsackievirus A-16 pneumonitis in adult.	2007-07	18214187
Sufficiently important difference for common cold: severity reduction.	2007-06-06	17548849
Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis.	2007-06	17482871
Genome-wide diversity and selective pressure in the human rhinovirus.	2007-05-03	17477878
Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.	2007-04	17239967
Enteroviral infections in children with malignant disease: a 5-year study in a single institution.	2007-04	16959324
Gateways to clinical trials.	2006-12	17235418
An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study.	2006-09-06	16956406
Gateways to clinical trials.	2006-06	16845450
Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.	2006-05	16467135
Investigation of treatment failure in neonatal echovirus 7 infection.	2006-03	16511392
The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.	2006-01	16397289
Current status of anti-picornavirus therapies.	2006	16611122
Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.	2005-12	16199099
[Rhinovirus diseases: pathogenesis, diagnostics and treatment].	2005-11-11	16279553
Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.	2005-10	16150864
Pharmacokinetics of antivirals in neonate.	2005-09	16085374
Coxsackievirus-induced myocarditis: new trends in treatment.	2005-08	16107202
Viral encephalitis: a review of diagnostic methods and guidelines for management.	2005-05	15804262
Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold.	2005-01-28	15673581
Pleconaril--an advance in the treatment of enteroviral infection in immuno-compromised patients.	2005-01	15571999
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.	2004-05-08	15135598
Neonatal coxsackie B virus infection-a treatable disease?	2004-04	14986123
Presentation, diagnosis, and management of enterovirus infections in neonates.	2004	14969566

Patents

Sample Use Guides

In Vivo Use Guide

200 mg TID or 400 mg TID for 7 days

Route of Administration: Oral

In Vitro Use Guide

Pleconaril’s antiviral activity was determined in a multicycle, virus-cell-based cytopathic effect (CPE) reduction assay in HeLa cells. The compound proved to be active against HRV strains from both the HRV-A (HRV09, HRV29, HRV85 and HRV89) and HRV-B group (HRV14, HRV70, and HRV86) with a 50 % effective concentrations (EC50’s) ranging from 0.01 μM to 15 μM.

Name

Type

Language

VP-63843

Preferred Name

English

PLECONARIL

Official Name

English

PLECONARIL [MI]

Common Name

English

pleconaril [INN]

Common Name

English

VP63843

Code

English

WIN63843

Code

English

Pleconaril [WHO-DD]

Common Name

English

PLECONARIL [MART.]

Common Name

English

WIN-63843

Code

English

PLECONARIL [USAN]

Common Name

English

3-(4-(3-(3-METHYL-5-ISOXAZOLYL)PROPOXY)-3,5-XYLYL)-5-TRIFLUOROMETHYL)-1,2,4-OXADIZOLE

Common Name

English

Classification Tree Code System Code

WHO-ATC

J05AX06